Renal cell cancer risk is associated to smoking and Obesity (hypertension is a corollary risk we claim). These 2 conditions lead to Hypoxia generally through sleep Apnea which in turn leads to a relative increase of Hemoglobin. The rise of Hemoglobin increases the portion of Desaturated hemoglobin. After many years of such exposure desaturated Heme enhances Phosphorylation at Tyr-530 of the SRC leading to its deactivation. In some individuals with the right MEK, suppression pf the SRC could lead to persistent amplification at the MEK which is a versatile activator of almost all signals, but particularly VEGF receptor. This in turn usually lead to papillary cancers. Amplification of signal transduction started at the MEK (which amplifies almost all major known pathways) will lead to increased ubiquitination and proteasome destruction of the HYPOXIA-inducible factor (following the Von Hippel-Lindau model. This will lead to clear cell cancer. Associated desaturated Heme and hypoxia at the mitochondria will participate in the transformation (and possibly the Atypia/clear cell transformation). The preponderance and center piece role of MEK amplification and subsequent VGEF/PDGF will justify the "bloody" nature of kidney cancers, and vessel involvement in these diseases (MEK is the driver Mutation in papillary cancers). IT ALSO EXPLAINS WHY SUTENT, NEXAVAR WORKS. AND MITOCHONDRIAL DISTURBANCES AND SECONDARY AMPLIFICATION OF AKT, THE MTOR INHIBITORS WORK IN RENAL CANCERS (MTOR participates more in clear cells) (proof of concept pending)
In Western society, obesity is increasing, and so is Sleep Apnea. Also, we live in closed homes (in some regions such as Texas and Louisiana, Mosquitoes are not helping) the level of dust participates in the increased level of allergic Rhinitis/ upper respiratory ailments. It is not unusual to sleep and wake with closed Nostrils. In obese individuals, this compounds the hypoxic episodes and worsened and prolonged hypoxia. And we are back to depression of SRC, activation of MEK---akt, MAPK and so forth.
Keeping your nostrils open at night appears to be a critical strategy in preventing renal cancer, particularly in patients with breathing issues. Lung cancer may be reduced for non smokers, but I wont touch that speculation, but do remember the role of VEGF in non-smoker lung cancers!
The involvement of PDGF which is by the way affected by Sutent seems to open a window in the frequency of strokes and heart attacks at night! That's another debate to have...!
MTOR inhibitor in combination with Anti-VGEF/ MEK could have a significant role in non smoker lung cancer.?
Velcade could have a role in VHL prevention ? and in Pheochromocytoma?
Avastin and Mtor inhibitor could treat Leiomysarcoma of the Uterus if you follow this logic!
A FREED CPRIT AND THE NIH COULD HELP!
Showing posts with label phosphorylation. Show all posts
Showing posts with label phosphorylation. Show all posts
Wednesday, February 6, 2013
Tuesday, February 5, 2013
BUTEIN, A POWERFUL INHIBITOR
As we speak with the University of Texas in El Paso, the CRBCM would like to look further into the clinical use of a potent Inhibitor in a phase I study. We believe this compound will have a significant role in Triple Negative Breast Cancer. Butein, a derivative of Charcone, a powerful anti-Oxidant and known anti-inflammatory used in ASIA, seems to have a global inhibitory effect. It is one of the 3 inhibitors of the SRC, it is a Glutathione inhibitor, Blocker of EGF, inhibitor of IKK, and of the NF-kB signal transduction pathway, cause phosphorylation of the AKT, reduction of Cyclin D1 and D2, activation of WAF1/p21 and KIP1/p27, Iron induced inhibitor of Xanthine Oxidase (love that enzyme since I first learned about Asthma).
This Butein stuff is a global inhibitor. If you add this to MTOR inhibitors, you may end up with too toxic a combination for any cancer! This would be an overwhelming attack on cells!
It has demonstrated powerful Ex-vivo activity against breast and prostate cancer cell lines, and is empirically used against Gastric cancer.
This global and versatile inhibitor, Butein, should have activity in Sarcoma since it inhibits SRC and potentially the fibroblast. Other Inhibitors of SRC, heme supported phosphorylation and CYIKYYF. (of note CDK1, PTRC and PTK2)
Gave you so many letters, lets move to gene Nomenclature please! we are still working hard at the CRBCM!
This Butein stuff is a global inhibitor. If you add this to MTOR inhibitors, you may end up with too toxic a combination for any cancer! This would be an overwhelming attack on cells!
It has demonstrated powerful Ex-vivo activity against breast and prostate cancer cell lines, and is empirically used against Gastric cancer.
This global and versatile inhibitor, Butein, should have activity in Sarcoma since it inhibits SRC and potentially the fibroblast. Other Inhibitors of SRC, heme supported phosphorylation and CYIKYYF. (of note CDK1, PTRC and PTK2)
Gave you so many letters, lets move to gene Nomenclature please! we are still working hard at the CRBCM!
Saturday, February 2, 2013
MYRISTOYLATION, A TRUE COMMITMENT AT THE CELLULAR MEMBRANE!
Proliferation, growth and spread of cancers is mainly driven by phenomena occurring at the membrane. A Molecular structure called SRC or sarc (for sarcoma) is anchored there, and Myristoylation is the process that keep it there. SARC or SRC
Wikipedia suggests:
Proto-oncogene tyrosine-protein kinase Src is an enzyme that in humans is encoded by the SRC gene.[1]
Src (pronounced "sarc" as it is short for sarcoma) is a proto-oncogene encoding a tyrosine kinase originally discovered by J. Michael Bishop and Harold E. Varmus, for which they were awarded the 1989 Nobel Prize in Physiology or Medicine.[2] It belongs to a family of non-receptor tyrosine kinases called Src family kinases. The discovery of Src family proteins has been instrumental to the modern understanding of cancer as a disease where normally healthy cellular signalling has gone awry.
This gene is similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene.[3]
==============================================================
In fact, SRC gene is at the center of Metastatic process through interaction with cell adhesion molecules, growth factors and many signal transduction pathways:
Wikipedia:
Interactions
Src (gene) has been shown to interact with
MET ACTIVITY INDUCED BY SRC ACTIVATION BY PHOSPHORYLATION SEEMS TO BE DETERMINED BY THE TYPE OF GROWTH FACTOR INDUCED. THROUGH HGFR, IT LEADS TO EMBRYONIC DEVELOPMENT IN THE EARLY CELL, AND TO WOUND HEALING IN RELEVANT TISSUE (SKIN), AND THROUGH HGF, IT LEADS TO MESENCHYMAL DIFFERENTIATION.
THROUGH MET, SRC LEADS TO RAS, PI3K/MAP K AND STAT EFFECTS
PHENOMENA AT THE MEMBRANE, A TRUE HISTORY, STILL UNFOLDING.
PLEASE ALSO NOTE CONFORMATION RAPPROCHEMENT BETWEEN SRC AND THE C-ABL WHERE IMITIMAB /GLEEVEC ACTS! SRC, CENTER OF METASTASIS, IS AN INTRODUCTION TO OUR FUTURE DISCUSSIONS.
Wikipedia suggests:
Src (gene)
From Wikipedia, the free encyclopedia
 |
This article needs attention from an expert on the subject. (March 2011) |
| V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 PDB rendering based on 1a07. |
|||||||||||
|
|||||||||||
| Identifiers | |||||||||||
| Symbols | SRC; ASV; SRC1; c-SRC; p60-Src | ||||||||||
| External IDs | OMIM: 190090 MGI: 98397 HomoloGene: 21120 ChEMBL: 267 GeneCards: SRC Gene | ||||||||||
| EC number | 2.7.10.2 | ||||||||||
|
|||||||||||
| RNA expression pattern | |||||||||||
 |
|||||||||||
 |
|||||||||||
| More reference expression data | |||||||||||
| Orthologs | |||||||||||
| Species | Human | Mouse | |||||||||
| Entrez | 6714 | 20779 | |||||||||
| Ensembl | ENSG00000197122 | ENSMUSG00000027646 | |||||||||
| UniProt | P12931 | P05480 | |||||||||
| RefSeq (mRNA) | NM_005417.3 | NM_001025395.2 | |||||||||
| RefSeq (protein) | NP_005408.1 | NP_001020566.1 | |||||||||
| Location (UCSC) | Chr 20: 35.97 – 36.03 Mb |
Chr 2: 157.42 – 157.47 Mb |
|||||||||
| PubMed search | [1] | [2 | |||||||||
Src (pronounced "sarc" as it is short for sarcoma) is a proto-oncogene encoding a tyrosine kinase originally discovered by J. Michael Bishop and Harold E. Varmus, for which they were awarded the 1989 Nobel Prize in Physiology or Medicine.[2] It belongs to a family of non-receptor tyrosine kinases called Src family kinases. The discovery of Src family proteins has been instrumental to the modern understanding of cancer as a disease where normally healthy cellular signalling has gone awry.
This gene is similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene.[3]
==============================================================
In fact, SRC gene is at the center of Metastatic process through interaction with cell adhesion molecules, growth factors and many signal transduction pathways:
Wikipedia:
Interactions
Src (gene) has been shown to interact with
- AR,[19][20][21]
- ARNT,[22]
- AHR,[22]
- ADRBK1,[23]
- ADRB3,[24]
- BCAR1,[25][26][27][28][29][30]
- CD44,[31]
- DAB2,[32]
- DDEF1,[33]
- DAG1,[34]
- EPHB2,[35][36]
- EGFR,[37][38][39]
- EPS8,[40]
- ESR1,[19][41][42][43]
- ESR2,[19][43]
- GNB2L1,[44]
- GRB2,[23][45]
- GRIN2A,[46][47]
- HNF1A,[48]
- KHDRBS1,[49][50][51][52][53]
- MT-ND2,[54]
- MUC1,[55][56]
- NCOA6,[57][58][59][60]
- PDE6G,[23]
- PLD2,[61]
- PRKCZ,[62]
- PTK2,[26][30][63][64][65][66]
- PTK2B,[38][67][68]
- RAF1,[69]
- RASA1,[70][71]
- RARA,[42][72]
- RICS,[73]
- SRF,[74]
- SHB,[75]
- STAT1,[37][76]
- STAT3,[77] and
- WAS.[78][79]
See also
Genatlas:- c-SRC is non receptor tyrosine kinase, direct effector of G proteins
- c-SRC plays a role in the regulation of embryonic development and cell growth
- c-SRC has an appreciable role in the organization of the Golgi apparatus, which may be linked to its involvement in protein transport from the Golgi apparatus to the endoplasmic reticulum
- c-SRC has an appreciable role in the organization of the Golgi apparatus, which may be linked to its involvement in protein transport from the Golgi apparatus to the endoplasmic reticulum
- monopalmitoylated SFK required for VEGF mitogenic signaling with SRC and FYN, but maintaining distinct properties in the regulation of VEGF-mediated endothelial cell events (Pubmed 16400523)
- c-SRC regulates Golgi structure and KDELR1-dependent retrograde transport to the endoplasmic reticulum
- c-SRC has a key role in the maintenance of epithelial integrity (Pubmed 18305002)
- c-SRC is crucially involved in the ghrelin-mediated Akt activation (Pubmed 19262695)
- non palmitoylated SFK (Src-family tyrosine kinase), rapidly exchanged between the plasma membrane and late endosomes/lysosomes (suggest that SFK trafficking is specified by the palmitoylation state in the SH4 domain) (Pubmed 19258394)
- major kinase implicated in PTK2 phosphorylation, and is directly translocated from focal adhesions to membrane ruffles, thereby promoting formation of new adhesion complexes (Pubmed 19066724)
- interacting with PDLIM4 and PTPN13 (PDLIM4 suppresses SRC activation through interacting with SRC and PTPN13, allowing PTPN13-dependent dephosphorylation of SRC at the activation loop) (Pubmed 19307596)
- c-SRC inhibits SGK1-mediated phosphorylation hereby restoring the WNK4-mediated inhibition of ROMK channels thus suppressing K secretion) (Pubmed 19706464)
- c-SRC binds DVL2, a key phosphoprotein in Wnt signaling, at two positions: an SH3-binding domain and a C-terminal domain (Pubmed 19920076)
- ----------------------------------------------------------------------------------------------
- THIS SRC IS PIVOTAL AND CENTER TO ALL ACTIVITY INVOLVING THE SPREAD AND MAINTENANCE OF CANCER. IT IS SOMEWHAT CELL AND SPECIES SPECIFIC.
- WE PURPOSELY LEFT THE DASATINIB REFERENCE HERE TO INDICATE THAT SCIENTIST ARE TRYING TO TARGET THIS CROSS ROAD MOLECULAR STRUCTURE.
- IT'S ACTIVITY AT THE MET PROTEIN INSURE CANCER GROWTH AND VASCULARIZATION THROUGH MET EFFECT ON ANGIOGENESIS.
- REMEMBER MET DISTURBANCES ARE PROMINENT IN PAPILLARY RENAL CELL CANCER.
MET ACTIVITY INDUCED BY SRC ACTIVATION BY PHOSPHORYLATION SEEMS TO BE DETERMINED BY THE TYPE OF GROWTH FACTOR INDUCED. THROUGH HGFR, IT LEADS TO EMBRYONIC DEVELOPMENT IN THE EARLY CELL, AND TO WOUND HEALING IN RELEVANT TISSUE (SKIN), AND THROUGH HGF, IT LEADS TO MESENCHYMAL DIFFERENTIATION.
THROUGH MET, SRC LEADS TO RAS, PI3K/MAP K AND STAT EFFECTS
PHENOMENA AT THE MEMBRANE, A TRUE HISTORY, STILL UNFOLDING.
PLEASE ALSO NOTE CONFORMATION RAPPROCHEMENT BETWEEN SRC AND THE C-ABL WHERE IMITIMAB /GLEEVEC ACTS! SRC, CENTER OF METASTASIS, IS AN INTRODUCTION TO OUR FUTURE DISCUSSIONS.
Subscribe to:
Posts (Atom)